Literature DB >> 1662531

Detection by a human monoclonal antibody of a glycoprotein associated with malignant proliferation of mammary epithelial cells.

S A Imam1, L A Mills, C R Taylor.   

Abstract

A tumour-associated antigen (TAA.62) with an apparent mol. wt. of 62 kd, identified by a human monoclonal antibody (IgG2, kappa-light chain), was found to be expressed at elevated levels in the cytoplasmic compartment of malignant as compared with normal mammary epithelial cells in both tissues and cultured cells. Increased levels of cytoplasmic expression of the antigen were also observed in malignant cells of cervix, colon, kidney, lung, and stomach. The patterns of expression of TAA.62 in cultured cells mirrored those of tissues and the antigen was expressed at elevated levels in the established breast cancer lines or oncogenically transformed mammary carcinoma cell line (tumourigenic) compared with the immortalised mammary epithelial cell line (non-tumourigenic). Aliquots of TAA.62 were purified to homogeneity from the conditioned-medium of malignant and immortalised breast cells by immunoaffinity chromatography using immobilised anti-TAA.62 antibody, and gel filtration. Both preparations of TAA.62 yielded a single band with an apparent molecular weight of 62 kd under reducing condition on sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and both were identical in terms of size and immunoreactivity to anti-TAA.62 antibody. However, TAA.62(T) isolated from tumourigenic cell lines itself interacted with a cell surface molecule having an apparent molecular weight of 160 kd on both the malignant and immortalised cells: TAA.62(I) isolated from immortalized cell lines, showed no comparable interaction. Scatchard analysis of the concentration-dependent binding of TAA.62(T) to 160 kd-receptor molecule revealed a 2.6 x 10(4) binding sites per cell. The association constant of such binding was determined to be approximately 16.6 nM. Finally, addition of anti-TAA.62 antibody to culture medium resulted in the inhibition of proliferation of the malignant cells, but showed no effect on the normal cells. The results suggest that TAA.62 may interact as a ligand with its 160 kd cell surface receptor with a possible growth related function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662531      PMCID: PMC1977871          DOI: 10.1038/bjc.1991.455

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Generation and immunohistological characterization of human monoclonal antibodies to mammary carcinoma cells.

Authors:  A Imam; M M Drushella; C R Taylor; Z A Tökés
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  A novel immunoperoxidase procedure of using human monoclonal antibodies for the detection of cellular antigens in tissue sections.

Authors:  A Imam; M M Drushella; C R Taylor
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

4.  Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32.

Authors:  J J Starling; R J Cote; P Marder; M J Borowitz; D A Johnson
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients.

Authors:  M V Haspel; R P McCabe; N Pomato; N J Janesch; J V Knowlton; L C Peters; H C Hoover; M G Hanna
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

6.  Use of xenograft tissue for the initial screening of human monoclonal antibodies by immunohistological technique.

Authors:  A Imam; E Stephanian
Journal:  J Immunol Methods       Date:  1988-11-10       Impact factor: 2.303

7.  Transformation of human mammary epithelial cells by oncogenic retroviruses.

Authors:  R Clark; M R Stampfer; R Milley; E O'Rourke; K H Walen; M Kriegler; J Kopplin; F McCormick
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

8.  Human-human hybridomas for the study of anti-tumor immune response in patients with colorectal cancer.

Authors:  P Borup-Christensen; K Erb; J C Jensenius; B Nielsen; S E Svehag
Journal:  Int J Cancer       Date:  1986-05-15       Impact factor: 7.396

9.  Biochemical and immunological characterizations of antigens recognised by human monoclonal antibodies.

Authors:  A Imam; C R Taylor
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.